CC BY 4.0 · Libyan International Medical University Journal 2023; 08(02): 089-090
DOI: 10.1055/s-0043-1771359
Letter to the Editor

Substandard and Falsified Medical Products: Time to Arrest Their Growth

1   Department of Community Medicine, Sri Balaji Vidyapeeth – Deemed to be University, Medical Education Unit Coordinator and Member of the Institute Research Council, Shri Sathya Sai Medical College and Research Institute, Ammapettai, Chengalpattu District, Tamil Nadu, India
,
Rasdita Nurhidayati
2   Department of Medical Education, Lambung Mangkurat University, Banjarmasin, Kalimantan, Indonesia
› Author Affiliations
 

Dear Sir

Substandard and falsified medical products refer to those medications or products that are developed with the intention to duplicate or substitute certified products.[1] [2] Based on the incidents reported in the last quarter of the year 2022 and in January 2023, it was found that in excess of 300 people lost their lives across seven nations owing to the consumption of cough syrups, which had diethylene glycol and ethylene glycol in significantly higher concentrations.[3] This calls for the need to take stringent and urgent measures to prevent, identify, and urgently respond to the incidents of such events in the future.[2] [3]

As it is a problem that involves multiple stakeholders, it is quite essential that we adopt a strategy that targets the involvement of all the concerned stakeholders.[1] [4] This has to begin with the involvement of policymakers, which must take necessary measures to identify and remove all substandard products, ensure circulation of only approved medical products, carry out periodic inspections of medicine production sites, expand the surveillance network in pharmaceutical markets, and ensure strict implementation of existing legal provisions, failing which offenders should be strictly punished.[4] [5]

The next important stakeholder is the manufacturing industry, which should purchase required chemicals from licensed suppliers, ensure holistic testing of the received chemicals, and maintain quality assurance standards, and all the records making the entire process accountable.[2] [3] [4] Finally, the distributors should check for signs of any contaminated product, engage in the distribution and sale of products approved by registered agencies, maintain records, and essentially involve trained personnel to monitor the entire process.[1] [2] [3] The role of each of these stakeholders is important and indispensable.[3] [4]

In conclusion, the circulation of substandard and falsified medical products in the commercial market is a major global public health hazard. This calls for the need to adopt a multipronged approach targeting different stakeholders to safeguard human lives.

Zoom Image

#

Conflict of Interest

None declared.


Address for correspondence

Saurabh RamBihariLal Shrivastava, FAIMER, MD Community Medicine, PGDHHM, DHRM, FCS, M.Phil (HPE), ACME
Department of Community Medicine, Shri Sathya Sai Medical College and Research Institute
SBV Chennai Campus, Shri Sathya Sai Nagar, Ammapettai, Chengalpattu District, Tamil Nadu - 603108
India   

Publication History

Article published online:
05 September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India


Zoom Image